Valiant Evo US Clinical Trial

Data from the Valiant Evo US trial (NCCT02652949) and Valiant Evo International trial
(NCT02625324) were combined to create the global cohort of 100 total subjects, in order
obtain 87 evaluable subjects. The two protocols are identical, and the trials were run
simultaneously to enroll subjects concurrently in the United States (US) and Outside United
States (OUS). The poolability on the primary endpoint between US and OUS data will be
assessed using Fisher's exact test during the data analysis. Data for both trials will be
combined and presented as a pooled analysis.

Inclusion Criteria:

1. Subject is ≥18 years old.

2. Subject understands and voluntarily has signed and dated the Informed Consent Form
approved by the Sponsor and by the Ethics Committee for this study.

3. Subject presents a Descending Thoracic Aortic Aneurysm (DTAA) which is localized below
the ostium of Left Subclavian Artery (LSA) and above the ostium of celiac trunk

4. Subject has a DTAA that is one of the following:

1. A fusiform aneurysm with a maximum diameter that:

- is ≥ 50 mm and/or:

- is > 2 times the diameter of the non-aneurysmal thoracic aorta and/or:

- is < 50 mm and has grown ≥ 5 mm within previous 12 months

2. A saccular aneurysm or a penetrating atherosclerotic ulcer

5. Subject's anatomy must meet all of the following anatomical criteria as demonstrated
on contrast-enhanced CT and/or on contrast-enhanced Magnetic Resonance Angiogram (MRA)
obtained within four (4) months prior to implant procedure:

1. Proximal and distal non-aneurysmal aortic neck diameter measurements must be ≥ 16
mm and ≤ 42 mm;

2. Proximal non-aneurysmal aortic neck length must be ≥ 20 mm (for FreeFlo
configuration) and ≥ 25 mm (for Closed Web configuration) distal to the left
common carotid artery (LCCA). Note: Proximal aortic neck length may include
covering the LSA (with or without discretionary revascularization) when necessary
to optimize device fixation and maximize aortic neck length. If occlusion of the
LSA ostium is required to obtain adequate neck length for fixation and sealing,
transposition or bypass to the LSA may be warranted.

3. Distal non-aneurysmal aortic neck length must be ≥ 20 mm

6. Subject has adequate arterial access site or can tolerate a conduit that allows
endovascular access to the aneurysmal site with the delivery system of the appropriate
sized device chosen for the treatment.

Exclusion Criteria:

1. Subject has a life expectancy of less than 1 year

2. Subject is participating in another investigational drug or device study which would
interfere with the endpoints and follow-ups of this study.

3. Subject is pregnant.

4. Subject requires planned placement of the covered proximal end of the stent graft to
occur in zones 0 or 1.

5. Subject has a thoracic aneurysm with a contained rupture or localized at the
anastomosis of a previous graft (pseudo-/false aneurysm).

6. Subject has a mycotic aneurysm.

7. Subject has a dissection (type A or B) or an intramural hematoma or an aortic rupture
in addition to the thoracic aneurysm.

8. Subject requires emergent aneurysm treatment, e.g., trauma or rupture.

9. Subject has received a previous stent or stent graft or previous surgical repair in
the ascending and/or descending thoracic aorta, and/or in the aortic arch.

10. Subject requires surgical or endovascular treatment of an infra-renal aneurysm at the
time of implant

11. Subject has had previous surgical or endovascular treatment of an infra-renal aortic
aneurysm.

12. Treatment with the Valiant Evo Thoracic Stent Graft would require intentional
revascularization of the brachio-cephalic artery or the left common carotid artery or
the celiac trunk.

13. Subject has had or plans to have a major surgical or interventional procedure within
30 days before or 30 days after the planned implantation of the Valiant Evo Thoracic
Stent Graft. This does not include planned procedures that are needed for the safe and
effective placement of the stent graft (i.e., carotid/subclavian transposition,
carotid/subclavian bypass procedure).

14. Subject has a significant and/or circumferential aortic mural thrombus at either the
proximal or distal attachment sites that could compromise fixation and seal of the
implanted stent graft.

15. Subject has a connective tissue disease (e.g., Marfan's syndrome, aortic medial
degeneration).

16. Subject has a bleeding diathesis or coagulopathy, or refuses blood transfusion.

17. Subject has had a Myocardial Infarction (MI) within 3 months of the procedure.

18. Subject has had a Cerebrovascular Accident (CVA) within 3 months of the procedure.

19. Subject has a known allergy or intolerance to the device materials

20. Subject has a known allergy to anesthetic drugs

21. Subject has a known hypersensitivity or contraindication to anticoagulants, or
contrast media, which is not amenable to pretreatment.

22. Subject has active or systemic infection at the time of the index procedure.